Human Fecal NGAL (LCN2) ELISA

The Human Fecal NGAL (LCN2) ELISA is intended for the quantitative determination of human neutrophil gelatinase-associated lipocalin (Lipocalin-2 or NGAL) in feces and urine.

For Research Use Only. Not for use in diagnostic procedures.

For Laboratory Professional Use Only.

NOT FOR SALE OUTSIDE THE U.S.

Test Principle of the Human Fecal NGAL (LCN2) ELISA

The Human Fecal NGAL (LCN2) ELISA is designed, developed, and produced for the quantitative measurement of human NGAL in stool samples. The assay utilizes the “sandwich” technique with selected antibodies that bind to various epitopes of NGAL.

Assay standards, controls, and patient samples are added directly to wells of a microtiter plate coated with antibody to human NGAL and incubated at room temperature for one hour. The plate is then washed, and horseradish peroxidase (HRP) conjugated anti-NGAL is added to each well. After an additional incubation period, a “sandwich” of solid-phase polyclonal antibody – human NGAL – HRP-conjugated antibody is formed. The unbound antibodies and buffer matrix are removed in the subsequent washing step.

To detect this immunocomplex, the well is then incubated with a substrate solution in a timed reaction, which is terminated with an acidic reagent (i.e., ELISA stop solution). The absorbance is then measured in a spectrophotometric microplate reader. The enzymatic activity of the immunocomplex bound to the wall of each microtiter well is directly proportional to the amount of human NGAL in the test sample.

A standard curve is generated by plotting the absorbance versus the respective human NGAL concentration for each standard on a point-to-point or 4-parameter curve fitting. The concentration of human NGAL in test samples is determined directly from this standard curve.